Limited Quantities Available! Order Today and Enjoy Free Shipping on Orders Over $100!
A condition where fat accumulates in the liver, often driven by fructose metabolism—can lead to inflammation and insulin resistance.
Fructose is uniquely lipogenic, meaning it turns into fat more efficiently than other sugars—directly in the liver. This fat buildup can occur even in lean individuals, especially when endogenous fructose is produced under stress or high-carb intake, silently progressing into non-alcoholic fatty liver disease (NAFLD).
SugarShield is designed to support metabolic health at the root. By helping manage the effects of fructose metabolism, it aids the body in maintaining healthy liver fat levels and reducing the cellular stress that leads to long-term dysfunction.
Fatty liver is a buildup of fat in liver cells, often without symptoms at first. Over time, it can progress to inflammation (NASH), fibrosis, cirrhosis, and liver failure.
The most common non-alcoholic cause is fructose overconsumption, which drives liver fat synthesis via de novo lipogenesis.
Fructose is taken up by the liver and rapidly converted into fat, depleting energy and generating uric acid. Even without sugar, endogenous fructose production can continue the cycle.
Fatty liver contributes to:
- Insulin resistance
- Inflammation
- Higher cholesterol
- Increased disease risk
By targeting fructose metabolism directly—with fructokinase inhibitors and uric acid reducers—we believe fatty liver can be reversed at the metabolic source, not just masked through calorie reduction."